anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a composition containing a kind of platelet which is produced by the contact of a platelet with a medium used in a new method of preserving platelets, erythrocytes and other akaryocytes in a powder form for a long period of time.  <P>SOLUTION: Platelets can be preserved for a long period of time by the contact of the platelets with the composition through a medium. The medium contains an anticoagulant, a cryoprecipitate and a coagulase. The long term preservation of platelets comprises the following steps. Step (a): To prepare a solution in which the anticoagulant, the cryoprecipitate and the coagulase are dissolved in an ordinary physiologic saline. Step (b): To obtain a solution containing platelets by adding a medium containing the platelets to the solution in step (a) and keeping it standstill. Step (c): To freeze-dry the platelet solution obtained in step (b). A kind of medium to preserve other akaryocytes is presented.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Uterine atony is a major contributor to postpartum hemorrhage. We previously proposed the novel histological concept of postpartum acute myometritis (PAM) to elucidate the pathophysiology of uterine atony. This concept involves the infiltration of macrophages and neutrophils, as well as mast cell and complement activation in the myometrium. However, the pathological mechanism underlying uterine atony in the context of PAM remains unclear. Herein, we focused on uterine contraction-associated proteins (CAPs) including connexin 43 (Cx43), oxytocin receptors (OXR), prostaglandin receptors EP1, EP3, FP, and protease-activated receptor (PAR)-1. This follow-up study aimed to compare CAP expression between PAM and control groups. We selected 38 PAM subjects from the cases enrolled in our amniotic fluid embolism registry between 2011 and 2018. Control tissues from 10 parturients were collected during cesarean section. We stained the myometrial tissues with the following CAP markers, inflammatory cell markers, and other markers: Cx43, OXR, EP1, EP3, FP, PAR-1, C5a receptor, tryptase, neutrophil elastase, CD68, β-actin, and Na+/K+-ATPase. The immunostaining-positive areas of Cx43, OXR, EP1, EP3, and FP standardized by β-actin in the PAM tissue were significantly smaller than in the control group, whereas those of PAR-1 and Na+/K+-ATPase increased significantly in the PAM group. The Cx43- and OXR-positive areas correlated negatively with the immunostaining-positive cell numbers of CD68 and tryptase with halo, respectively. PAM may impair individual and synchronized myocyte contraction, leading to uterine atony refractory to uterotonics. Further cell-based studies are needed to elucidate the molecular mechanism by which inflammatory cells suppress CAP expression.
The invention belongs to the technical field of photothermal therapy antibacterial, and relates to a biological agent with strong bacterial adsorption and photothermal performance and application thereof. The biological agent is prepared from biological microspheres, and the biological microspheres are prepared by the following method: degreasing sunflower bee pollen, removing protein and pollen cavity content, washing to obtain pollen wall, oven drying, sulfuric acid treatment, and oven drying. The biological agent is prepared by the following method: placing biological microsphere and curdlan in normal saline, mixing, and irradiating with near infrared light. The invention discovers that the biological microsphere can achieve the antibacterial effect through the adsorption of bacteria. Thus, the biological microspheres may be used as a bacterial adsorbent and/or bacteriostatic agent. The invention also finds that the biological agent can be used for skin infection wound surface to promote skin healing. Therefore, the biological agent can be used as a skin infection wound healing medicine.
Only interlaminar epidural steroid injection will be administered to patients in this arm with the same method as in the other arms (one session, week 0). Staying active will be the only recommendation, and no exercise prescription will be provided.
Systems and methods for simulating structures and images are disclosed. The techniques described herein can include obtaining a first image of a subject. The techniques can include determining a location for simulating a structure within the first image. The techniques can include simulating, according to the location, a shape for the structure. The techniques can include generating a mask according to the location and the shape for the structure. The techniques can include applying the mask to the first image to generate a second image simulating the structure.
A transdermal drug delivery device is disclosed. The device is in the form of a self adhesive bandage with a drug containing layer (12). The layer (12) also contains visually indiscernible micro-spheres (11) that contain an opioid antagonist. The micro-spheres (11) have a mean size from about 1 to 500 um in diameter. If used correctly the drug with migrate through the skin of a person that it is adhered to. If the device is tampered with the opioid antagonist will mix with the drug rendering it unsuitable for the purpose of abuse.
Mucoceles of the paranasal sinuses are benign, expansile lesions that develop secondary to sinus ostia obstruction. Presenting signs and symptoms vary widely but frequently include frontal headache and swelling, as well as visual changes and globe displacement depending on orbital involvement in the case of frontal sinus mucoceles. Given the potential for orbital or intracranial involvement, urgent imaging with computed tomography (CT) is important for patients with symptoms concerning for a frontal sinus mucocele. Definitive treatment is surgical. In this article, we report a case of a 50-year-old male who presented to a primary care clinic with a painful forehead mass, found to have a frontal sinus mucocele with erosion through the frontal bone that was eventually treated surgically. We also summarize presenting signs and symptoms of frontal mucoceles reported in the literature as these are important for clinicians to be familiar with, considering the potential emergent complications.
Pharmaceutical compositions for treating neoplastic disorders and uses thereof are provided. Said pharmaceutical compositions comprise stabilized chlorite solutions (e.g. WFlO) and a fluoropyrimidine, 5 -FU, or a 5-FU prodrug (e.g.  capecitabine, doxifluridine, UFT, S-1, or BOF-A2). The use of the above stabilized chlorite solution in combination with a fluoropyrimidine dramatically improves the quality of life index (QOL) of a patient undergoing cancer chemotherapy. Cancers that can be treated include cancers of the pancreas, gastrointestinal, head, neck, and breast.
In the 2017 guidelines, perioperative glycemic control with a blood glucose level of \<200 mg/dL is recommended for patients with and without DM. Ideal blood glucose control should provide good glycemic control with a minimal incidence of hypoglycemia.
Benzo-heterocyclic derivs. of formula (I), in which a is 1-4 and X, Y, Z, R and R1 can be various radicals, with anti-allergic activity, are made by treating a cpd. of formula (II), in which B can be various radicals and other symbols are as in (I), under cyclisation or ring closure conditions, followed by opt. alkylation or acylation of the prod. - The cyclisation reaction takes place in inert solvent at reflux temp. or below.
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
The purpose of this study is to assess the safety and efficacy of TA-ER in the treatment of rotator cuff disease. The study will enroll 65 patients in a longitudinal case series level IV study using extended release triamcinolone to treat shoulder pain from rotator cuff disease. Inclusion criteria will be shoulder pain without a history of trauma and physical exam consistent with rotator cuff tendinitis, impingement syndrome or rotator cuff tear. Patients will have normal Xrays or Xrays indicative of chronic cuff tearing and a musculoskeletal ultrasound indicating an intact rotator cuff, partial cuff tearing or cuff tear. Patients will undergo an ultrasound guided injection of TA-ER into the subacromial space from a lateral access point at the time of the examination. They will be monitored for any immediate adverse effects. Patient reported outcomes measures will be recorded with online questionnaires which include a Visual Analog Scale (VAS), Single assessment numeric evaluation (SANE), Veteran's Rand 12 (VR-12) and American Shoulder and Elbow Scale (ASES) and will be recorder pre-treatment and at 2, 4, 8 and 12 and 24 weeks post treatment. Patients will be asked to follow up for an in person evaluation at 4 weeks, 12 weeks and 24 weeks post injection.
BACKGROUND: Osteonecrosis of the femoral head (ONFH) is a significant postoperative complication following femoral neck fractures (FNFs) in adolescents, that has garnered considerable attention from researchers. Despite this interest, the incidence of ONFH in adolescents post-FNF surgery has not been extensively evaluated. To contribute to the body of research, we performed a meta-analysis utilizing articles sourced from multiple databases, with an emphasis on the rate of ONFH occurrence in young adolescents following FNF surgery.
OBJECTIVE: The purpose of this study was to investigate the incidence of ONFH after FNFs in adolescents worldwide and analyse potential risk factors affecting its occurrence to provide guidance for the treatment and rehabilitation after FNFs in adolescents and reduce the incidence of ONFH.
METHODS: A comprehensive search of medical literature databases, including MEDLINE, Web of Science, the Cochrane Library, and Embase, was conducted to identify relevant studies on ONFH and its associated risk factors after surgical treatment for FNFs in adolescents, covering the period from the establishment of the database to April 2024. Studies that did not meet the inclusion criteria were excluded. The study was conducted based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA). Literature extraction, management, and data entry were performed using Zotero 6.0 and Excel 2016. The meta-analysis was conducted using R Studio 4.2.2. Subgroup analysis, sensitivity analysis, and assessment of publication bias were performed to explore sources of heterogeneity and evaluate the reliability of the results. This study has been registered on Prospero. (registration number: CRD4202452794; date of registration: 03/04/2024) RESULTS: A total of 17 publications involving 862 patients with FNFs were included in this meta-analysis. The findings revealed that the incidence of ONFH after FNF surgery in adolescents was 24.02% [95% CI (0.2118, 0.2712)]. The included studies demonstrated good consistency, and no publication bias was observed.
CONCLUSION: This study revealed that the incidence of ONFH after FNFs in adolescents is high (24.02%). Early screening and effective treatment of postoperative patients are crucial.
The investigators will conduct a large prospective Canadian multi-centre diagnostic cohort study. The primary diagnostic test evaluated will be CT-perfusion. The reference standard will be the complete clinical evaluation of brainstem functions. Comatose patients at high risk of neurological death exempt of confounding factors (e.g. hypothermic patients, use of long-acting sedatives, etc.) will be included. All patients will undergo CT-perfusion of the head (with CT-angiography reconstructions) followed by a complete NDD assessment. Both CT-perfusion and the clinical exam will be performed by independent assessors blinded from each others' interpretation. The primary endpoints will be the sensitivity and specificity of CT-perfusion to confirm NDD. Safety endpoints will be CT-perfusion -related adverse events (i.e. contrast-induced kidney injury, new hemodynamic instability while undergoing CT-perfusion). The true negative, true positive, false negative and false positive for CT-angiography obtained from the CT-perfusion source images when compared to the reference standard as well as when compared to the CT-Perfusion will also be reported. The sensitivity and specificity of CT-angiography compared to the reference standard and to CT-perfusion along with corresponding 95% confidence intervals will be calculated. Individual patient and population pharmacokinetics of analgesics and sedatives will be determined. To better investigate the impact of residual circulating sedative or narcotic levels on the accuracy of CT-Perfusion and CT-Angiography, Receiver Operating Characteristics (ROC) curves for varying levels of narcotic or sedative thresholds and compute the ROC area under the curve for each threshold will be plotted. To assess the immune phenotype, peripheral blood mononuclear cells activation will be evaluated by flow cytometry and cytokines by multiplex analyses. Nanovesicles fraction will be isolated from the plasma by ultracentrifugation and antigenic content and enzymatic activity. The plasma will finally be analysed by ELISAs and multiplex analyses to determine the levels of pro-inflammatory cytokines.
The invention discloses a targeted anti-cancer molecule gefitinib phthalocyanine conjugate, and a preparation method and application thereof. The molecular formula of the gefitinib phthalocyanine conjugate is C56+2nH42+4nO5+nClFN12Zn (n=2-8). Gefitinib with an alkoxyl long chain is introduced into the periphery of a metal phthalocyanine large ring, so the amphipathicity and the biocompatibility can be improved, and the targeting property of a photosensitizer is enhanced. The gefitinib phthalocyanine conjugate is difficult to aggregate, so the cellular uptake ratio is increased and the activity of the photosensitizer in photodynamic therapy is also enhanced. The compound has single structure, is not provided with an isomer, and is easy to purify. A synthesis method is simple, little in side reaction, high in yield, easily available in raw materials, low in cost and favorable for industrialized production.
Stroke is a major cause of morbidity and mortality worldwide. Stroke can lead to varying degrees of oropharyngeal dysphagia (25-85% of patients) and respiratory muscle dysfunction associated with an increase in medical complications such as bronchoaspiration, malnutrition and death. Dysphagia is present in a significant proportion of patients admitted to Rehabilitation (up to 85% depending on series) in stroke. Standard swallow therapy consists of educational intervention aimed to improve self-management of dysphagia and protect the airway, oral exercises to improve lingual praxis, and compensatory techniques based on videofluoroscopic findings. Recent studies suggest that IEMT can improve swallowing efficacy and reduce eventual bronchoaspiration events.

Nutritional status appears in 9-67% of patients with acute and subacute stroke and has an impact on functional outcomes and provides information about the risk of hospitalization and death. Stroke patients are at risk of developing malnutrition because of neurologic impairments related to feeding (chewing, deglutition and self-feeding) that can result in a poor food intake. To date, there is only few studies on prevalence and influence of malnutrition in stroke.
Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
This is a single arm study that is planed to enroll 60 patients with advanced malignant solid tumor and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.
BACKGROUND: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and glomerulonephritis is uncommon in children. We sought to characterize the histological and clinical features of the disease and report on risk factors for adverse outcomes in a pediatric cohort.
METHODS: Retrospective single-center cohort of all pediatric (< 20 years) patients diagnosed with ANCA-associated glomerulonephritis (AAGN) by kidney biopsy between 2002 and 2022 at Johns Hopkins University. Histological and clinical features were extracted from the medical record. Clinical, laboratory, and histological findings were analyzed to determine the association with kidney failure (KF) and/or death.
RESULTS: A total of 17 patients were identified (GPA n = 7, MPA = 10) with a median age of 15 years (IQR 12-17) at presentation, a slight female predominance (59%), with seven patients reaching the composite outcome of death (n = 1) or kidney failure (n = 6). There was no difference in presenting clinical symptoms or extra-renal manifestations between the two groups. Univariable Cox regression identified several factors associated with an increased hazard of endpoint including the degree of global or segmental sclerosis, interstitial fibrosis and tubular atrophy (IFTA), C3 and C1q staining, presence of subendothelial deposits, and proteinuria. Multivariable regression was not performed due to the small sample size. We saw a trend towards increased utilization of plasma exchange and a decrease in cyclophosphamide utilization in the more recent era. There was no association between treatment modality and outcome.
CONCLUSIONS: Pediatric AAGN is a rare disease associated with significant morbidity. We identified glomerulosclerosis and IFTA on histology, and proteinuria on initial presentation as risk factors for KF/death.
The intervention consists of in person counseling and cash payment. The participants receive 25 Euro per week if they have succeeded in quitting smoking. Quitting smoking is evaluated by carbon monoxide measurements twice a week.
PURPOSE: A composition of antibiotic complex for animals containing Lyncomycin hycrocholoride and Florfenicol is provided to have the high storage stability, no irritation to skins, lower Minimum Inhibitiry Concentration(MIC) for pathogenic bacteria than Lyncomycin hycrocholoride, Florfenicol, Chloramphenicol, a wide range of suppression zone, high susceptibility and no antibiotic residue in milk when spray treatment is conducted. CONSTITUTION: Lyncomycin hycrocholoride to Florfenicol weight ratio is from, 1 to 1, to 1 to 10. In a composition, Lyncomycin hycrocholoride to Florfenicol weight ratio is 1 to 5. The composition is highly useful for a food rot, a skin wound and the prevention or treatment of bacterial infection in surgical areas. Animals are chickens, pigs, cows, horses, dogs, cats, ducks, goats and sheep. The composition is used for solution for external use. The solution for external use includes a suppository, a disinfectant, an ointment, mouthwash, gargle, enema, cataplasm, an aerosol propellant, inhalation, eye drops, ear drops, nasal sprays, a cleansing reagent or a bath.
The invention provides a vegetable oil containing bFGF. The vegetable oil is formed by the following steps: linking the nucleotide sequence of the human bFGF to a 3' terminal of the nucleotide sequence of the oil protein of the oil expression plasmid p1390ONE to obtain the recombinant plasmid; transforming oil crops with the recombinant plasmid to express bFGF, and extracting the oil of seeds of the oil crops. The invention also provides a vegetable oil gel containing bFGF. The vegetable oil gel is formed by mixing the vegetable oil containing bFGF with a gel matrix of the oil, wherein the gel matrix comprises the following components in percentage by weight: 1-5% of carboxyethyl cellulose, 5-40% of glycerol, 0.01-0.1% of methylparaben, 0.01-0.1% of propylparaben and the balance of injection water. The vegetable oil gel containing bFGF comprises 30% of the vegetable oil containing bFGF and 70% of the gel matrix. The vegetable oil gel can be stored at 37 DEG C for 12 months, has no mould phenomenon and also has no change in physicochemical indices such as appearance and pH value. The vegetable oil gel can be stored at 4 DEG C for 12 months, and the activity of bFGF is not obviously changed.
An object of the present invention is to offer novel purine derivatives which exhibit an inhibitory action to nasal mucus secretion and are useful as pharmaceuticals, etc. and pharma-ceutically acceptable salts thereof.    The purine derivatives of the present invention are novel compounds which are represented by the following general formula (I).              (I) [In the formula, R is alkyl or cycloalkyl, or optionally-substituted phenyl or phenylalkyl; R' is hydrogen or -COOX; and X is alkyl, alkenyl, alkoxyalkyl, phenyl or phenylalkyl]    The compounds of the present invention are useful as thera-peutic and preventive agents to various types of rhinitis accom-panied by acceleration of nasal mucus secretion and by sneezing reflex such as allergic rhinitis.  Moreover, the compounds of the present invention are able to be administered orally and exhibit low toxicity, little side effect and high safety.  Accordingly, a continuous administration for long term is possible and they have a very high utility as the drugs.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely gastroenterology, and can be used for treating chronic cholecystitis. For this purpose, with underlying the drug-induced therapy in the patients with diagnosed anxiodepressive disorder, the antidepressant azaphen is administered for 30 days. Clinically evident mood disorders require the dosage 25 mg 3 times a day, while in subclinically evident mood disorders, the dosage is 25 mg 2 times a day; it is combined with transcutaneous magnetic-laser therapy by wave length 0.89 mcm, with a magnetic cap 150 mT for 2 min with covering a solar plexus on a projection of a gall bladder and to a projection of a duodenum: if observing evident pain syndrome of frequency 820 Hz followed by gradual frequency reduction with remitting clinical manifestations of the disease to 80 Hz; mild pain syndrome of frequency 360 Hz followed by gradual frequency reduction with remitting clinical manifestations of the disease to 80 Hz; In the absence of pain syndrome of frequency 80 Hz. ^ EFFECT: method allows reducing a degree of manifestation of pain syndrome, prolonging remission, reducing frequency of recurrences due to normalised daily chronobiorhythm, vegetative balance, corrected mood disorders. ^ 1 ex, 2 tbl